Sarepta Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Sarepta Therapeutics

05/08/2026 22:01

Sarepta Therapeutics, Inc. SRPT.OQ reported a quarterly adjusted loss of 5 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $1.89.  The mean expectation of twenty three analysts for the quarter was for earnings of 26 cents per share. Wall Street expected results to range from -17 cents to $1.07 per share.
Revenue fell 34.3% to $401.25 million from a year ago; analysts expected $364.34 million. 
Sarepta Therapeutics, Inc.'s reported EPS for the quarter was a loss of 5 cents​.
The company reported a quarterly loss of $4.89 million.
Sarepta Therapeutics, Inc. shares had fallen by 8.8% this quarter and lost 23.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 57% in the last three months.​ 
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 9 "strong buy" or "buy," 12 "hold" and 6 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."
Wall Street's median 12-month price target for Sarepta Therapeutics, Inc. is $20.00, about 18% above its last closing price of $16.39
This summary was machine generated from LSEG data August 5 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.26
-0.05
Missed
Mar. 31 2026 
0.99
2.88
Beat
Dec. 31 2025 
-1.23
-3.93
Missed
Sep. 30 2025 
-0.82
-0.01
Beat